NEW UNIQUE METHOD
EARLY DETECTION OF PROGRESSIVE DISEASE
We measure what really matters!
Early detection of progressive tumor disease is important for clinical management. There is an unmet need for a reliable biomarker for treatment response, in both research and in clinical application.
The enzyme Thymidine Kinase 1 (TK1) is up-regulated in tumor cells from which it is released into the blood during their turnover. Increased serum TK1 protein is associated with tumor growth, but AroCell’s unique new product, the TK 210 ELISA kit is the only available CE marked immunoassay for it. TK1 monitoring offers a step towards individualized cancer therapy.
CONVENIENT AND EASY TEST
A blood test saves time, reduces cost and is convenient for the patient. AroCell uses ELISA, a standard technology platform already extensively used in clinical laboratories.
STRONG COMPETITIVE ADVANTAGE
TK1 enzyme activity has been used for many years for prognosis and treatment monitoring of hematological malignancies. However, recent studies have demonstrated that a large fraction of the TK1 protein in patients with solid tumor disease is inactive.
As an immunoassay, the AroCell TK 210 ELISA kit measures the total mass of TK1, whether the protein is active or not. This increases the value of TK1 in studying samples from patients with solid tumors and opens new research opportunities for making prognoses and monitoring the effects of therapy.
A GOOD PATENT POSITION
AroCell has a good patent position based on a method to produce antibodies against specific exposed TK1 epitopes. This together with a unique composition of the assay buffer has allowed the company to overcome sensitivity and specificity problems that have hindered previous attempts to develop a similar assay. Clinical results indicate that the AroCell TK 210 ELISA antibodies are able to quantify TK1 with the required sensitivity and specificity.